Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 92.11 USD -0.56% Market Closed
Market Cap: 114.7B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Gilead Sciences Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gilead Sciences Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
AMGN
ALNY
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Income from Continuing Operations
-$332.3m
CAGR 3-Years
27%
CAGR 5-Years
17%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%

See Also

What is Gilead Sciences Inc's Income from Continuing Operations?
Income from Continuing Operations
113m USD

Based on the financial report for Sep 30, 2024, Gilead Sciences Inc's Income from Continuing Operations amounts to 113m USD.

What is Gilead Sciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-36%

Over the last year, the Income from Continuing Operations growth was -98%. The average annual Income from Continuing Operations growth rates for Gilead Sciences Inc have been -75% over the past three years , -47% over the past five years , and -36% over the past ten years .

Back to Top